No $400B Mega Merger? AstraZeneca Rises, Bristol Myers Falls as Report Denies Deal
Shares in British pharma giant AstraZeneca ($AZN) jumped about 5% on Wednesday morning while those in top U.S. biopharma company Bristol-Myers Squi...
Astrazeneca Plc (AZN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Gotham Asset Management Joel Greenblatt | 2,868 | $565,627 | +38% | 0% |
| 2. | NWI Management Hari Hariharan | 25,000 | $4,930,000 | 0.28% | |
| 3. | Two Sigma Advisors John Overdeck And David Siegel | 0 | $0 | 0% | |
| 4. | ADAR1 Capital Management Daniel Schneeberger | 0 | $0 | 0% | |
| 5. | Samjo Capital Andrew N. Wiener | 0 | $0 | 0% |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $185.78 | 11,893 | $2,209,481.54 | 19,262 | 2026-05-20 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 487,420 | $92,316,944 | 0.79% | |
| 2. | 46,736 | $8,862,080 | 1.35% | |
| 3. | 23,593 | $4,473,705 | 0.45% | |
| 4. | 7,412 | $1,395,505 | 0.53% | |
| 5. | 5,058 | $959,213 | 0.59% |
News See All
AstraZeneca Falls, Bristol Myers Rises on Early Merger Talks for Potential $400B Deal
British drugmaker AstraZeneca ($AZN) and U.S.-based Bristol Myers Squibb ($BMY) are in early talks about a potential merger that could create a $40...
Attractive Growth Profile Positions AstraZeneca PLC (AZN) as Opportunity
Harris Oakmark recently released its second-quarter 2026 investor letter for the “Oakmark Global Fund”. A copy of the letter can be downloaded here.
Can AstraZeneca PLC (AZN) Grow Its Rare Disease Portfolio Through Ultomiris Expansion?
TheFly reported on June 15 that AZN announced that its supplemental Biologics License Application (sBLA) for Ultomiris (ravulizumab) was accepted and granted Priority Review by the U.S.
10 Best Weight Loss Drug Stocks to Buy in 2026
The anti-obesity drug (AOM) market in the United States is rapidly changing structurally.
12 Best Growth Stocks Trading in Oversold Territory
On June 11, Emily Roland, the Co-Chief Investment Strategist at Manulife John Hancock Investment Management, joined 'Squawk Box' on CNBC to discuss where investors can find opportunity right now.
Jim Cramer Discussed 27 Stocks, Like Arm and Lockheed, and the Recent Market Sell-Off
In this article, we will look at the stocks Jim Cramer discussed on Mad Money, along with the recent sell-off in the market.
AstraZeneca's (AZN) CARES Phase III Clinical Programme Fails to Meet Primary End Point
AstraZeneca PLC (NYSE:AZN) is one of the best stocks to buy now for long term growth. AstraZeneca PLC (NYSE:AZN) reported on May 29 that the global CARES Phase III clinical programme showed that treatment...
10 Best Stocks to Buy Now for Long Term Growth
On May 29, Andrew Slimmon, Senior Portfolio Manager at Morgan Stanley, appeared on CNBC’s 'Closing Bell' to talk about equity markets, whether investors should keep riding the tech winning streak, and...
CDT Equity Advances AstraZeneca PLC (AZN)'s AZD5904 Into PCT Patent Protection Stage
TheFly reported on May 6 that CDT Equity announced that AZD5904, a selective inhibitor of human myeloperoxidase originally licensed from AstraZeneca PLC (NYSE:AZN), has entered the Patent Cooperation ...
Hedge Fund Resource Center